COVID -19 VACCINE INITIATIVES IN INDIA

(updates shared from Dept of Microbiology SRM DENTAL COLLEGE, Ramapuram)

Candidates – 8 its trial stage, efficacy under consideration.

CANDIDATE	
ZyCovi– Di (Zydus cadilla, Ahmedabad)	Study design: Pegylated Interferon alpha-2b,
	ZyCoV-D is a plasmid DNA vaccine candidate.
	When delivered into the host cells, the
	plasmid DNA is known to translate into the
	viral protein and trigger a strong cellular and
	humoral immune response.
	Status : Phase III trial, same candidate in Mexico in
	Phase II trial.
Biological E (Hydrabad)in collaboration with MIT	Study Design : used as Recombinant Protein Ag.
	Status : Phase II& III. started
HGCO-19	Study Design : 1 st mRNA Vaccine. In INDIA
Genova biotech –pune based with HDT biotech	
seattle USA	Status : phase I &II to start
Nasal Vaccine – Bharat Biotech	Study Design : Indian firm Bharat Biotech will be commencing Phase I trials of its
	intranasal Covid-19 vaccine
	Status : phase I trial.
Sputnik V-	Study Design : India To Make 300 Million Of
Dr .Reddy;s lab & Gamelaya lab –Russia	Sputnik V Covid Vaccines. 4 large
	manufacturers (Hetero Biopharma)has
	already announced a deal with the RDIF to
	make more than 100 million doses of Sputnik
	V, whose efficacy has been found to be more
	than 91% in trials done outside India.
	In India phase III trial .
NVX-CoV 2373 - Novavax's	Study Design : Nanoparticle vaccine , M atrix
	M Adjuvan
	American company NOVAX with serum
	institute – Pune 2 nd vaccine by serum institute
	Status – phase III trial
Covaxin – Bharat Biotech	Study Design:indigenous, inactivated vaccine.
ICMR - NIV	The vaccine received DCGI approval for Phase I
	& II Human Clinical Trials.
	Bharat Biotech received DCGI approval for
	Phase 3 clinical trials in 26,000 participants in
	over 25 centres across India.
Bharat Biotech- Thomson & Jefferson university	Inactivated Rabies Vector Preclinical phase
	mactivated names vector riechnical phase